Immunogenicity Information in Labeling

This webinar has been approved for 1.5 contact hours of continuing education for pharmacists, physicians, and nurses. Please see detailed announcement for additional information.

ABOUT THIS WEBINAR

During this webinar, FDA will:

• Highlight why immunogenicity is important to consider for drug development

• Discuss the draft guidance for industry, Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling — Content and Format (February 2022). When final, this guidance will represent FDA’s current thinking on this topic.

• Discuss creation of the new dedicated subsection 12.6 for immunogenicity information (Immunogenicity subsection) in the CLINICAL PHARMACOLOGY section of labeling

• Provide an overview on how to develop the Immunogenicity subsection

• Describe when and how to incorporate immunogenicity information in other sections of labeling

• Provide recommendations on when to update immunogenicity information in labeling

INTENDED AUDIENCE

Pharmaceutical industry staff who include immunogenicity information in labeling for their biological products [specifically human therapeutic protein products licensed under section 351(a) of the Public Health Service Act] and certain select drug products (regulated under section 505 of the Federal Food, Drug, and Cosmetic Act) with immunogenicity assessments (e.g., heparins, oligonucleotides, and peptides).

FDA SPEAKERS

Daphne Guinn, Ph.D.
Regulatory Health Project Manager
Office of Clinical Pharmacology (OCP)
Office of Translational Science (OTS) | CDER | FDA

Eric Brodsky, M.D.
Associate Director, Labeling Policy Team
Office of New Drug Policy (ONDP)
Office of New Drugs (OND) | CDER | FDA

FDA RESOURCES

• Draft guidance for industry, Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling — Content and Format (February 2022). When final, this guidance will represent FDA’s current thinking on this topic.

• Prescription Drug Labeling Resources

• Immunogenicity development guidances:

• Immunogenicity Assessment for Therapeutic Protein Products (August 2014)

• Immunogenicity Testing of Therapeutic Proteins Developing and Validating Assays for Anti-drug Antibody Detection (January 2019)

• Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (April 2015)

• Considerations in Demonstrating Interchangeability to a Reference Product (May 2019)

• Immunogenicity-Related Considerations for Low Molecular Weight Heparin (February 2016)

• ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (May 2021)

Want to get more information about FDA resources and medical supply companies online? Pharmasources would be a great choice.

CONTINUING EDUCATION

Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.

This course has been:

• approved for 1.5 contact hours of continuing education for pharmacists, physicians and nurses. Please see detailed announcement for more information.

• pre-approved by RAPS as eligible for a maximum of 12 credits for a two day event (appropriate to real-time attendance) towards a participant’s RAC recertification upon full completion.

• pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.

• pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant’s RQAP re-registration.

• approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.

TECHNICAL INFORMATION

• To optimize your webinar experience, use Chrome when viewing Adobe Connect in a browser.

• Please contact info@sbiaevents.com for all technical questions.

• If you encounter any technical issues before or during the event, please visit the Technical Issues SupportExternal Link Disclaimer.

• Test your PC for use with Adobe ConnectExternal Link Disclaimer prior to the day of the event. Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.